Le Lézard
Classified in: Health
Subjects: RCL, CFG

Advisory - Recall: One lot of Riva-Risperidone 0.25 mg tablets recalled due to a packaging error


OTTAWA, ON, Oct. 9, 2021 /CNW/ -

Summary

Issue
Laboratoire Riva Inc. is recalling one lot (lot C9323) of Riva-Risperidone 0.25 mg tablets due to a packaging error. Some bottles may incorrectly contain only Riva-Gabapentin 100 mg capsules. Pharmacists may not recognize the error and inadvertently repackage and dispense pill bottles that contain the wrong medication. 

Risperidone is a prescription drug used in adults to treat the symptoms of schizophrenia and related psychotic disorders, as well as bipolar disorder. It may also be used for the short-term treatment of severe dementia related to Alzheimer's disease.

Gabapentin is a prescription drug used for treating epilepsy (seizures).

If you miss a dose of Risperidone, you may not have proper control of your condition or its symptoms may worsen.

By taking Gabapentin instead of Risperidone, you may:

If you notice any of these signs or symptoms, contact your health care professional immediately.  

Riva-Risperidone 0.25 mg tablets are yellowish-orange, oblong-shaped coated tablets, with "0.25" on one side and "R" on the other side. Riva-Gabapentin 100 mg capsules are white hard gelatin capsules, with "Gabapentin / 100 mg" printed on the capsule in blue ink.

Health Canada is monitoring the company's recall. If additional safety information is identified, Health Canada will take appropriate action and inform Canadians as needed. 

Affected products

Company

Product

DIN

Lot #

Expiration Date

Laboratoire Riva Inc.

Riva-Risperidone 0.25 mg tablets
100-tablet bottles

02283565

C9323

2022-MR-31

What you should do

Additional information for health professionals:

Riva-Risperidone 0.25 mg tablets (yellowish-orange, oblong-shaped coated tablets, with

Riva-Gabapentin 100 mg capsules (white hard gelatin capsules, with

Riva-Risperidone 0.25 mg bottle that incorrectly contains only Riva-Gabapentin 100 mg capsules (CNW Group/Health Canada)

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 20:10
We are advised by Hidden River Eating Disorder Residential Treatment that journalists and other readers should disregard the news release, Hidden River Announces Insurance Contract with Blue Cross Blue Shield, issued 16-May-2024 over PR Newswire....

at 20:00
Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced the appointment of Mark S. de Jong, PhD, to the newly created position of Chief Technical Officer (CTO). Dr. de Jong, joins Full-Life with 43...

at 19:20
Whitman-Walker Institute, which leverages research, policy, and education to advance health equity nationwide, says it's standing by to further inform the chair of the U.S. House Committee on Education and the Workforce and others about the strong...

at 18:50
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc....

at 18:46
Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRAtm (tarlatamab-dlle) for the...

at 18:42
Housecall Providers, a nonprofit home-based medical organization invites the community to Sellwood Park, Saturday, June 1, from noon ? 4:00 p.m. for an inspiring afternoon of learning, connection and some friendly competition. Toss...



News published on and distributed by: